Subcutaneous versus intravenous administration of rituximab: Pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Mao, Cheng Ping ^a   Brovarney, Martin R ^a   Dabbagh, Karim ^a   Birnböck, Herbert F ^b   Richter, Wolfgang F ^b   Del Nagro, Christopher J ^a,c  

^a Inflammation   (United States)

^b F Hoffmann La Roche   (Switzerland)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; HYALURONIDASE; RECOMBINANT DNA; RITUXIMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CELL SURFACE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; FEASIBILITY STUDY; LYMPHOCYTE DEPLETION; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHARMACOKINETICS; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTE SUBSETS; IMMUNOPHENOTYPING; INFUSIONS, SUBCUTANEOUS; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; LYMPHOCYTE DEPLETION; MACACA FASCICULARIS; MALE; RECEPTORS, COMPLEMENT 3D;

EID: 84893009815     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080533     Document Type: Article

References (33)

1. Hagemeister F (2010) Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70: 261-272. doi:10.2165/11532180-000000000-00000. PubMed: 20166765.
2. Keating GM (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70: 1445-1476. doi:10.2165/11201110-000000000-00000. PubMed: 20614951.
3. Genentech (2011) Inc.. Rituxan (Prescribing Information). Genentech, Inc., South San Francisco, CA
4. Haller MF (Oct. 22007) Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase. Pharm Technol Oct. 2. Retrieved onpublished at whilst December year 1111 from PharmTech.com website. Available: http://pharmtech.findpharma.com/pharmtech/Article/Converting-Intravenous-Dosing- to-Subcutaneous-Dosi/ArticleStandard/Article/detail/463578. Accessed 1 October 28, 2013
5. Hornberger J, Reyes C, Lubeck D, Valente N (2008) Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 49: 227-236. doi:10.1080/10428190701769665. PubMed: 18231908. (Pubitemid 351200289)
6. Ray JA, Carr E, Lewis G, Marcus R (2010) An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. Value Health 13: 346-357. doi:10.1016/S1098-3015(11)72374-9. PubMed: 20070643.
7. Vogel WH (2010) Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 14: E10-E21. doi:10.1188/10.CJON.E10-E21. PubMed: 20350882.
8. Kivitz A, Segurado OG (2007) HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab. Expert Rev Med Devices 4: 109-116. doi:10.1586/17434440.4.2.109. PubMed: 17359217. (Pubitemid 46522760)
9. Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F et al. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100: 768-773. doi:10.1182/blood-2002-01- 0159. PubMed: 12130484. (Pubitemid 34832599)
10. Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF et al. (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27: 3994-4001. doi:10.1200/JCO.2008.21.1128. PubMed: 19597025.
11. Ratner M (2010) Roche plans for more convenient-to-use Herceptin and Rituxan. Nat Biotechnol 28: 298. doi:10.1038/nbt0410-298. PubMed: 20379157.
12. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA et al. (2006) A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114: 230-241. doi:10.1016/j.jconrel.2006.05.027. PubMed: 16876899. (Pubitemid 44291844)
13. Frost GI (2007) Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 4: 427-440. doi:10.1517/17425247.4.4.427. PubMed: 17683255.
14. Glennie MJ, French RR, Cragg MS, Taylor RP (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44: 3823-3837. doi:10.1016/j.molimm.2007.06.151. PubMed: 17768100. (Pubitemid 47332625)
15. Vugmeyster Y, Howell K, McKeever K, Combs D, Canova-Davis E (2003) Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Int Immunopharmacol 3: 1477-1481. doi:10.1016/S1567-5769(03)00147-4. PubMed: 12946444. (Pubitemid 37025728)
16. Vugmeyster Y, Howell K, Bakshl A, Flores C, Canova-Davis E (2003) Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A 52: 101-109. PubMed: 12655653. (Pubitemid 37521508)
17. Loder F, Mutschler B, Ray RJ, Paige CD, Sideras P et al. (1999) B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 190: 75-89. doi:10.1084/jem.190.1.75. PubMed: 10429672. (Pubitemid 29330125)
18. Morcos PN, Zhang X, McIntyre C, Bittner B, Rowell L et al. (2013) Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. Int J Clin Pharmacol Ther 51(7): 537-548. doi:10.5414/CP201847. PubMed: 23547849.
19. Muchmore DB, Vaughn MD DE (2012) Accelerating and Improving the Consistency of Rapid-Acting Analog Insulin Absorption and Action for Both Subcutaneous Injection and Continuous Subcutaneous Infusion Using Recombinant Human Hyaluronidase. J Diabetes Sci Technol 6(4): 764-772. PubMed: 22920800.
20. Lindorfer MA, Wiestner A, Zent CS, Taylor RP (2012) Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? Oncoimmunology 1(6): 959-961. doi:10.4161/onci.20368. PubMed: 23162771.
21. Yin A, Li J, Hurst D, Visich J (2010) Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin's lymphoma. J Clin Oncol ASCO Annual Meeting Proceedings Vol 28 (May 20 Supplement): e13108
22. Bleeker WK, Munk ME, Mackus WJ, van den Brakel JH, Pluyter M et al. (2008) Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 140(3): 303-312. doi:10.1111/j.1365-2141.2007.06916.x. PubMed: 18045353.
23. Daydé D, Ternant D, Ohresser M, Lerondel S, Pesnel S et al. (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113(16): 3765-3772. doi:10.1182/blood-2008- 08-175125. PubMed: 19029438.
24. Mo CC, Njuguna N, Beum PV, Lindorfer MA, Vire B et al. (2013) Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. Haematologica. 98(8): 1259-1263. doi:10.3324/haematol. 2012.080929. PubMed: 23716541.
25. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y et al. (1996) Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26: 690-696. doi:10.1002/eji.1830260327. PubMed: 8605939. (Pubitemid 26091401)
26. Ghetie V, Ward ES (1997) FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18: 592-598. doi:10.1016/S0167- 5699(97)01172-9. PubMed: 9425738. (Pubitemid 28012280)
27. Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34: 687-709. doi:10.1007/s10928-007-9065-1. PubMed: 17636457. (Pubitemid 47477039)
28. Tabrizi MA, Tseng CM, Roskos LK (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11: 81-88. doi:10.1016/S1359-6446(05)03638-X. PubMed: 16478695. (Pubitemid 43227856)
29. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC et al. (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115: 5191-5201. doi:10.1182/blood-2010-01-263533. PubMed: 20223920.
30. Salar A, Bouabdallah R, McIntyre C, Sayyed P, Bittner B (2010) A two-stage phase Ib study to investigate the pharmacokinetics, safety and tolerability of subcutaneous rituximab in patients with follicular lymphoma as part of maintenance treatment. Blood 116: 21 (Abstract 2858)
31. Hoffmann-La Roche (2013) A study to compare subcutaneous versus intravenous MabThera (rituximab) in combination with chemotherapy in patients with chronic lymphocytic leukemia. Retrieved onpublished at whilst December year 1111 from ClinicalTrials.gov. Accessed 1 October 28.
32. Hoffmann-La Roche (2013) A study of MabThera (rituximab) subcutaneous vs. MabThera (rituximab) intravenous in patients with follicular non-Hodgkin's lymphoma. Retrieved onpublished at whilst December year 1111 from ClinicalTrials.gov. Accessed 1 October 28.
33. Hoffmann-La Roche (2013) A pharmacokinetic study of subcutaneous and intravenous MabThera (rituximab) in patients with follicular lymphoma. Retrieved onpublished at whilst December year 1111 from ClinicalTrials.gov. Accessed 1 October 28.